MEDINDIA
English
हिन्दी
Español
français
中文
Email
abobotulinumtoxinA
Botulinum Toxin Type A may increase the neuromuscular blocking activities of Pancuronium.
Acetyldigitoxin
Pancuronium may increase the arrhythmogenic activities of Acetyldigitoxin.
Aclidinium
Pancuronium may increase the anticholinergic activities of Aclidinium.
Alfentanil
The risk or severity of adverse effects can be increased when Pancuronium is combined with Alfentanil.
Alphaprodine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Alphaprodine.
Ambenonium
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Ambenonium.
AMBROXOL ACEFYLLINATE
The risk or severity of adverse effects can be increased when Ambroxol acefyllinate is combined with Pancuronium.
Ambroxol-Theophylline-7-Acetate
The risk or severity of adverse effects can be increased when Ambroxol acefyllinate is combined with Pancuronium.
Amikacin
Amikacin may increase the respiratory depressant activities of Pancuronium.
Aminophylline
The risk or severity of adverse effects can be increased when Aminophylline is combined with Pancuronium.
Arbekacin
Arbekacin may increase the respiratory depressant activities of Pancuronium.
Atracurium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Atracurium.
Atracurium Besylate
The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pancuronium.
Atropine
The risk or severity of adverse effects can be increased when Atropine is combined with Pancuronium.
Azosemide
Azosemide may decrease the neuromuscular blocking activities of Pancuronium.
Benactyzine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Benactyzine.
Bendroflumethiazide
The serum concentration of Bendroflumethiazide can be increased when it is combined with Pancuronium.
Benzthiazide
The serum concentration of Benzthiazide can be increased when it is combined with Pancuronium.
Benztropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Pancuronium.
Biperiden
The risk or severity of adverse effects can be increased when Biperiden is combined with Pancuronium.
Botulinum Toxin Type A
Botulinum Toxin Type A may increase the neuromuscular blocking activities of Pancuronium.
Bumetanide
Bumetanide may decrease the neuromuscular blocking activities of Pancuronium.
Buprenorphine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Buprenorphine.
Butorphanol
The risk or severity of adverse effects can be increased when Pancuronium is combined with Butorphanol.
Butylscopolamine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Butylscopolamine.
Capreomycin
Capreomycin may increase the neuromuscular blocking activities of Pancuronium.
Chlorothiazide
The serum concentration of Chlorothiazide can be increased when it is combined with Pancuronium.
Chlorphenoxamine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Chlorphenoxamine.
Chlortetracycline
Chlortetracycline may increase the neuromuscular blocking activities of Pancuronium.
Chlorthalidone
Chlorthalidone may decrease the neuromuscular blocking activities of Pancuronium.
Clindamycin
Clindamycin may increase the neuromuscular blocking activities of Pancuronium.
Codeine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Codeine.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Pancuronium is combined with Codeine.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Pancuronium is combined with Codeine.
Colistimethate
Colistimethate may increase the neuromuscular blocking activities of Pancuronium.
Cyclopenthiazide
The serum concentration of Cyclopenthiazide can be increased when it is combined with Pancuronium.
Cyclopentolate
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pancuronium.
Cyclosporine
Cyclosporine may increase the neuromuscular blocking activities of Pancuronium.
Darifenacin
The risk or severity of adverse effects can be increased when Darifenacin is combined with Pancuronium.
Demecarium
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Demecarium.
Demeclocycline
Demeclocycline may increase the neuromuscular blocking activities of Pancuronium.
Deslanoside
Pancuronium may increase the arrhythmogenic activities of Deslanoside.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Pancuronium.
Dexetimide
The risk or severity of adverse effects can be increased when Dexetimide is combined with Pancuronium.
Dextromoramide
The risk or severity of adverse effects can be increased when Pancuronium is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Dezocine.
Dicyclomine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pancuronium.
Digitoxin
Pancuronium may increase the arrhythmogenic activities of Digitoxin.
Digoxin
Pancuronium may increase the arrhythmogenic activities of Digoxin.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydrocodeine.
Dihydrostreptomycin
Dihydrostreptomycin may increase the respiratory depressant activities of Pancuronium.
Diphenhydramine
The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pancuronium.
Diphenoxylate
The risk or severity of adverse effects can be increased when Pancuronium is combined with Diphenoxylate.
Dipivefrin
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Dipivefrin.
Distigmine
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Distigmine.
Donepezil
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Donepezil.
Doxycycline
Doxycycline may increase the neuromuscular blocking activities of Pancuronium.
Doxycycline Anhydrous
Doxycycline may increase the neuromuscular blocking activities of Pancuronium.
Dyphylline
The risk or severity of adverse effects can be increased when Dyphylline is combined with Pancuronium.
Echothiophate
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Echothiophate.
Edrophonium
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Edrophonium.
Eluxadoline
Pancuronium may increase the constipating activities of Eluxadoline.
Ethacrynate
Etacrynic acid may decrease the neuromuscular blocking activities of Pancuronium.
Ethacrynic Acid
Etacrynic acid may decrease the neuromuscular blocking activities of Pancuronium.
Ethylmorphine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Ethylmorphine.
Fentanyl
The risk or severity of adverse effects can be increased when Pancuronium is combined with Fentanyl.
Fesoterodine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Fesoterodine.
Flavoxate
The risk or severity of adverse effects can be increased when Flavoxate is combined with Pancuronium.
Flavoxate Hydrochloride
The risk or severity of adverse effects can be increased when Flavoxate is combined with Pancuronium.
Framycetin
Framycetin may increase the respiratory depressant activities of Pancuronium.
Furosemide
Furosemide may decrease the neuromuscular blocking activities of Pancuronium.
Galantamine
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pancuronium.
Gentamicin
Gentamicin may increase the respiratory depressant activities of Pancuronium.
Ginkgo biloba extract
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Ginkgo biloba.
Glucagon
The risk or severity of adverse effects can be increased when Pancuronium is combined with Glucagon recombinant.
glucagon (rDNA)
The risk or severity of adverse effects can be increased when Pancuronium is combined with Glucagon recombinant.
Glycopyrronium
Pancuronium may increase the anticholinergic activities of Glycopyrronium.
Heroin
The risk or severity of adverse effects can be increased when Pancuronium is combined with Heroin.
Homatropine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Homatropine.
Human Secretin
The therapeutic efficacy of Human secretin can be decreased when used in combination with Pancuronium.
Hydrochlorothiazide
The serum concentration of Hydrochlorothiazide can be increased when it is combined with Pancuronium.
Hydrocodone
The risk or severity of adverse effects can be increased when Pancuronium is combined with Hydrocodone.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Pancuronium is combined with Hydrocodone.
Hydroflumethiazide
Hydroflumethiazide may decrease the neuromuscular blocking activities of Pancuronium.
Hydromorphone
The risk or severity of adverse effects can be increased when Pancuronium is combined with Hydromorphone.
Hyoscyamine
The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pancuronium.
incobotulinumtoxinA
Botulinum Toxin Type A may increase the neuromuscular blocking activities of Pancuronium.
Indapamide
The serum concentration of Indapamide can be increased when it is combined with Pancuronium.
Ipratropium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pancuronium.
Ipratropium cation
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pancuronium.
Isoflurophate
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Isoflurophate.
Kanamycin
Kanamycin may increase the respiratory depressant activities of Pancuronium.
kanamycin A
Kanamycin may increase the respiratory depressant activities of Pancuronium.
Levomethadyl
The risk or severity of adverse effects can be increased when Pancuronium is combined with Levomethadyl Acetate.
Levorphanol
The risk or severity of adverse effects can be increased when Pancuronium is combined with Levorphanol.
Lincomycin
Lincomycin may increase the neuromuscular blocking activities of Pancuronium.
Lithium
Lithium may increase the neuromuscular blocking activities of Pancuronium.
Lithium Cation
Lithium may increase the neuromuscular blocking activities of Pancuronium.
Magnesium Hydroxide
Magnesium hydroxide may increase the neuromuscular blocking activities of Pancuronium.
Magnesium Oxide
Magnesium oxide may increase the neuromuscular blocking activities of Pancuronium.
Magnesium Salicylate
Magnesium salicylate may increase the neuromuscular blocking activities of Pancuronium.
Magnesium Sulfate
Magnesium sulfate may increase the neuromuscular blocking activities of Pancuronium.
MAGNESIUM SULFATE ANHYDROUS
Magnesium sulfate may increase the neuromuscular blocking activities of Pancuronium.
Malathion
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Malathion.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pancuronium.
Mefloquine
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Mefloquine.
Memantine
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Memantine.
Meperidine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Pethidine.
Methadone
The risk or severity of adverse effects can be increased when Pancuronium is combined with Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Pancuronium is combined with Methadyl Acetate.
Methantheline
The risk or severity of adverse effects can be increased when Methantheline is combined with Pancuronium.
Methixene
The risk or severity of adverse effects can be increased when Pancuronium is combined with Metixene.
Methscopolamine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Methscopolamine.
Methscopolamine Bromide
The risk or severity of adverse effects can be increased when Pancuronium is combined with Methylscopolamine bromide.
Methyclothiazide
Methyclothiazide may decrease the neuromuscular blocking activities of Pancuronium.
Metoclopramide
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Metoclopramide.
Metolazone
The serum concentration of Metolazone can be increased when it is combined with Pancuronium.
Mianserin
Mianserin may increase the anticholinergic activities of Pancuronium.
Minaprine
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Minaprine.
Minocycline
Minocycline may increase the neuromuscular blocking activities of Pancuronium.
Mirabegron
The risk or severity of adverse effects can be increased when Pancuronium is combined with Mirabegron.
Morphine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Morphine.
Nabilone
Pancuronium may increase the tachycardic activities of Nabilone.
Nalbuphine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Nalbuphine.
Neomycin
Neomycin may increase the respiratory depressant activities of Pancuronium.
Neostigmine
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Neostigmine.
Netilmicin
Netilmicin may increase the respiratory depressant activities of Pancuronium.
Normethadone
The risk or severity of adverse effects can be increased when Pancuronium is combined with Normethadone.
O-PHENANTHROLINE
The therapeutic efficacy of Pancuronium can be decreased when used in combination with 1,10-Phenanthroline.
Octotropine Methylbromide
The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pancuronium.
Octylonium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Otilonium.
onabotulinumtoxinA
Botulinum Toxin Type A may increase the neuromuscular blocking activities of Pancuronium.
Opium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Opium.
Orphenadrine
The risk or severity of adverse effects can be increased when Orphenadrine is combined with Pancuronium.
Ouabain
Pancuronium may increase the arrhythmogenic activities of Ouabain.
Ovine Digoxin Immune Fab
Pancuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).
Oxitropium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Oxitropium.
Oxybutynin
The risk or severity of adverse effects can be increased when Oxybutynin is combined with Pancuronium.
Oxycodone
The risk or severity of adverse effects can be increased when Pancuronium is combined with Oxycodone.
Oxymorphone
The risk or severity of adverse effects can be increased when Pancuronium is combined with Oxymorphone.
Oxyphenonium
The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pancuronium.
Oxytetracycline
Oxytetracycline may increase the neuromuscular blocking activities of Pancuronium.
Oxytetracycline Anhydrous
Oxytetracycline may increase the neuromuscular blocking activities of Pancuronium.
Paregoric
The risk or severity of adverse effects can be increased when Pancuronium is combined with Morphine.
Paromomycin
Paromomycin may increase the respiratory depressant activities of Pancuronium.
Pentazocine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Pentazocine.
Physostigmine
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Physostigmine.
Pipecuronium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Pipecuronium.
Pirenzepine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Pancuronium.
Piretanide
Piretanide may decrease the neuromuscular blocking activities of Pancuronium.
Pirinitramide
The risk or severity of adverse effects can be increased when Pancuronium is combined with Piritramide.
Plazomicin
Plazomicin may increase the respiratory depressant activities of Pancuronium.
Polymyxin B
Polymyxin B Sulfate may increase the neuromuscular blocking activities of Pancuronium.
Polymyxin B Sulfate
Polymyxin B Sulfate may increase the neuromuscular blocking activities of Pancuronium.
Polythiazide
The serum concentration of Polythiazide can be increased when it is combined with Pancuronium.
Potassium Chloride
Pancuronium may increase the ulcerogenic activities of Potassium Chloride.
Pramlintide
Pramlintide may increase the anticholinergic activities of Pancuronium.
Procainamide
Procainamide may increase the neuromuscular blocking activities of Pancuronium.
Procyclidine
The risk or severity of adverse effects can be increased when Procyclidine is combined with Pancuronium.
Profenamine
The risk or severity of adverse effects can be increased when Ethopropazine is combined with Pancuronium.
Propantheline
The risk or severity of adverse effects can be increased when Propantheline is combined with Pancuronium.
Propantheline Bromide
The risk or severity of adverse effects can be increased when Propantheline is combined with Pancuronium.
Propiverine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Propiverine.
Propoxyphene
The risk or severity of adverse effects can be increased when Pancuronium is combined with Dextropropoxyphene.
Proscillaridin
Pancuronium may increase the arrhythmogenic activities of Proscillaridin.
Pyridostigmine
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Pyridostigmine.
Pyridostigmine Bromide
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Pyridostigmine.
Quinethazone
Quinethazone may decrease the neuromuscular blocking activities of Pancuronium.
Quinidine
Quinidine may increase the neuromuscular blocking activities of Pancuronium.
Quinine
Quinine may increase the neuromuscular blocking activities of Pancuronium.
Remifentanil
The risk or severity of adverse effects can be increased when Pancuronium is combined with Remifentanil.
rimabotulinumtoxinB
Pancuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.
Rivastigmine
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Rivastigmine.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pancuronium.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pancuronium.
Secretin
The therapeutic efficacy of Secretin can be decreased when used in combination with Pancuronium.
Sisomicin
Sisomicin may increase the respiratory depressant activities of Pancuronium.
Solifenacin
The risk or severity of adverse effects can be increased when Pancuronium is combined with Solifenacin.
Streptomycin
Streptomycin may increase the respiratory depressant activities of Pancuronium.
Sufentanil
The risk or severity of adverse effects can be increased when Pancuronium is combined with Sufentanil.
Sulpiride
Pancuronium may increase the anticholinergic activities of Sulpiride.
Tacrine
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Tacrine.
Tapentadol
The risk or severity of adverse effects can be increased when Pancuronium is combined with Tapentadol.
Tetracycline
Tetracycline may increase the neuromuscular blocking activities of Pancuronium.
Tetrahydrocannabinol
Pancuronium may increase the tachycardic activities of Dronabinol.
Theophylline
The risk or severity of adverse effects can be increased when Theophylline is combined with Pancuronium.
Theophylline anhydrous
The risk or severity of adverse effects can be increased when Theophylline is combined with Pancuronium.
Tiotropium
Pancuronium may increase the anticholinergic activities of Tiotropium.
Tobramycin
Tobramycin may increase the respiratory depressant activities of Pancuronium.
Tolterodine
The risk or severity of adverse effects can be increased when Tolterodine is combined with Pancuronium.
Topiramate
The risk or severity of adverse effects can be increased when Pancuronium is combined with Topiramate.
Torsemide
Torasemide may decrease the neuromuscular blocking activities of Pancuronium.
Tramadol
The risk or severity of adverse effects can be increased when Pancuronium is combined with Tramadol.
Trichlormethiazide
Trichlormethiazide may decrease the neuromuscular blocking activities of Pancuronium.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pancuronium.
Trihexyphenidyl Hydrochloride
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pancuronium.
Trimethaphan
The risk or severity of adverse effects can be increased when Trimethaphan is combined with Pancuronium.
Tropicamide
The risk or severity of adverse effects can be increased when Tropicamide is combined with Pancuronium.
Trospium
The risk or severity of adverse effects can be increased when Trospium is combined with Pancuronium.
Tubocurarine
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Pancuronium.
Tyrothricin
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Tyrothricin.
Umeclidinium
Pancuronium may increase the anticholinergic activities of Umeclidinium.
Vancomycin
Vancomycin may increase the neuromuscular blocking activities of Pancuronium.
Vecuronium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Vecuronium.
